Literature DB >> 35226310

Reirradiation of Recurrent and Second Primary Cancers of the Head and Neck: a Review of the Contemporary Evidence.

Paul J Kreinbrink1, Luke M Lewis1, Kevin P Redmond1, Vinita Takiar2,3,4.   

Abstract

OPINION STATEMENT: Recurrent and second primary head and neck cancers represent a clinical challenge due to frequently unresectable and/or locally advanced disease. Given that many of these patients have received definitive doses of radiation previously, reirradiation is associated with significant morbidity. Use of modern approaches such as conformal photon-based planning and charged particle therapy using protons or carbon ions allows for greater sparing of normal tissues while maintaining or escalating doses to tumor volumes. While the reirradiation data has consistently shown benefits to local control and even survival from escalation of radiotherapy dose, excessive cumulative doses can result in severe toxicities, including fatal carotid blowout syndrome. For all modalities, appropriate patient selection is of utmost importance. Large-scale trials and multi-institutional registry data are needed to standardize treatment modalities, and to determine optimal doses and volumes for reirradiation.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Head and neck squamous cell carcinoma; Proton; Recurrent and second primary head and neck cancer; Reirradiation; Salvage therapy; Toxicity

Mesh:

Year:  2022        PMID: 35226310     DOI: 10.1007/s11864-021-00936-y

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  32 in total

1.  Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses.

Authors:  Vinita Takiar; Adam S Garden; Dominic Ma; William H Morrison; Mark Edson; Mark E Zafereo; Gary B Gunn; Clifton D Fuller; Beth Beadle; Steven J Frank; William N William; Merrill Kies; Adel K El-Naggar; Randal Weber; David I Rosenthal; Jack Phan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-19       Impact factor: 7.038

2.  Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of AIRO-Head and Neck working group.

Authors:  Ester Orlandi; Pierluigi Bonomo; Letizia Ferella; Elisa D'Angelo; Marta Maddalo; Daniela Alterio; Gabriele Infante; Almalina Bacigalupo; Angela Argenone; Nicola Alessandro Iacovelli; Isacco Desideri; Bruno Meduri; Luca Triggiani; Stefania Volpe; Liliana Belgioia; Francesco Dionisi; Domenico Attilio Romanello; Carlo Fallai; Rosalba Miceli
Journal:  Head Neck       Date:  2019-07-29       Impact factor: 3.147

3.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

4.  Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.

Authors:  Sharon A Spencer; Jonathan Harris; Richard H Wheeler; Mitchell Machtay; Christopher Schultz; William Spanos; Marvin Rotman; Ruby Meredith; Kie-Kian Ang
Journal:  Head Neck       Date:  2008-03       Impact factor: 3.147

5.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang
Journal:  Lancet Oncol       Date:  2009-11-10       Impact factor: 41.316

6.  A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer.

Authors:  John A Vargo; Matthew C Ward; Jimmy J Caudell; Nadeem Riaz; Neal E Dunlap; Derek Isrow; Sara J Zakem; Joshua Dault; Musaddiq J Awan; Kristin A Higgins; Comron Hassanadeh; Jonathan J Beitler; Chandana A Reddy; Samuel Marcrom; Drexell H Boggs; James A Bonner; Min Yao; Mitchell Machtay; Farzan Siddiqui; Andy M Trotti; Nancy Y Lee; Shlomo A Koyfman; Robert L Ferris; Dwight E Heron
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-24       Impact factor: 7.038

7.  Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes.

Authors:  Alexander F Bagley; Adam S Garden; Jay P Reddy; Amy C Moreno; Steven J Frank; David I Rosenthal; William H Morrison; Gary Brandon Gunn; Clifton D Fuller; Shalin J Shah; Renata Ferrarotto; Erich M Sturgis; Neil D Gross; Jack Phan
Journal:  Head Neck       Date:  2020-08-09       Impact factor: 3.147

8.  Reirradiation with intensity-modulated radiation therapy for recurrent or secondary head and neck cancer: Meta-analysis and systematic review.

Authors:  Jeongshim Lee; In-Soo Shin; Woo Chul Kim; Won Sup Yoon; Woong Sub Koom; Chai Hong Rim
Journal:  Head Neck       Date:  2020-05-21       Impact factor: 3.147

9.  Intensity-Modulated Radiotherapy-Based Reirradiation for Head and Neck Cancer: A Multi-institutional Study by Korean Radiation Oncology Group (KROG 1707).

Authors:  Jeongshim Lee; Tae Hyung Kim; Yeon-Sil Kim; Myungsoo Kim; Jae Won Park; Sung Hyun Kim; Hyun Ju Kim; Chang Geol Lee
Journal:  Cancer Res Treat       Date:  2020-07-07       Impact factor: 4.679

10.  Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative.

Authors:  Matthew C Ward; Nadeem Riaz; Jimmy J Caudell; Neal E Dunlap; Derek Isrow; Sara J Zakem; Joshua Dault; Musaddiq J Awan; John A Vargo; Dwight E Heron; Kristin A Higgins; Jonathan J Beitler; Samuel Marcrom; Drexell H Boggs; Comron Hassanzadeh; Chandana A Reddy; James A Bonner; Min Yao; Mitchell Machtay; Farzan Siddiqui; Andy M Trotti; Nancy Y Lee; Shlomo A Koyfman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-06-17       Impact factor: 8.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.